Gyros Protein Technologies (formerly Gyros AB) is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. Gyrolab immunoassay platforms increase productivity and efficiency during development of biotherapeutics and vaccines, saving time, labor and sample. Major biopharmaceutical companies and their service providers utilize Gyrolab platforms to boost time-critical workflows and meet increasingly stringent regulatory demands.
Whether you need to accelerate assay development for preclinical R&D, facilitate upstream and downstream bioprocessing or meet critical data and time requirements for regulated bioanalysis, Gyros will put a new spin on what’s possible in your laboratory. Using nanoliter microfluidics, Gyros’ flow-through technology simplifies assay workflows by eliminating incubations and shortening run times to produce reliable data exhibiting 3- to 4-log dynamic range and minimal matrix interference.